亿帆医药：公司创新药F-627最快明年在美国本土实现直接发货

Core Viewpoint - The U.S. will impose a 100% tariff on patented and branded drugs starting October 1, which may impact pharmaceutical companies' operations and supply chains in the U.S. market [1] Company Response - Yifan Pharmaceutical has been monitoring U.S. tariff policies and is optimizing the supply chain and cost strategies for its innovative drug F-627 [1] - The company plans to shift the production and shipping of F-627 to the U.S. to mitigate the impact of tariffs, with the potential for local dispatch as early as next year [1] - Yifan Pharmaceutical asserts that the tariff policy will not have a significant adverse effect on the sales of F-627 in the U.S. market [1]